Compare HIO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIO | RZLT |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.9M | 352.1M |
| IPO Year | N/A | 2011 |
| Metric | HIO | RZLT |
|---|---|---|
| Price | $3.31 | $4.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $10.10 |
| AVG Volume (30 Days) | 723.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $1.07 |
| 52 Week High | $3.84 | $11.17 |
| Indicator | HIO | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 51.77 |
| Support Level | $3.19 | $3.69 |
| Resistance Level | $3.33 | $4.22 |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 75.00 | 66.52 |
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.